T1	Intervention 50 100	advanced and recurrent endometrial cancer patients
T2	Intervention 255 368	advanced or recurrent endometrial cancer patients participating in Gynecologic Oncology Group chemotherapy trials
T3	Intervention 912 925	1203 patients
